MY173548A - Fxa variant compositions - Google Patents
Fxa variant compositionsInfo
- Publication number
- MY173548A MY173548A MYPI2016700985A MYPI2016700985A MY173548A MY 173548 A MY173548 A MY 173548A MY PI2016700985 A MYPI2016700985 A MY PI2016700985A MY PI2016700985 A MYPI2016700985 A MY PI2016700985A MY 173548 A MY173548 A MY 173548A
- Authority
- MY
- Malaysia
- Prior art keywords
- fxa variant
- variant compositions
- compositions
- fxa
- hemostasis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 239000003114 blood coagulation factor Substances 0.000 abstract 1
- 230000023597 hemostasis Effects 0.000 abstract 1
- 230000004481 post-translational protein modification Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY173548A true MY173548A (en) | 2020-02-04 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2016700985A MY173548A (en) | 2013-09-24 | 2014-09-16 | Fxa variant compositions |
Country Status (19)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| PE20190661A1 (es) * | 2016-06-17 | 2019-05-08 | Portola Pharm Inc | Preparacion de derivados del factor xa |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| JP2008509688A (ja) * | 2004-08-17 | 2008-04-03 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 改変ビタミンｋ依存性ポリペプチド |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| DK2915564T3 (da) * | 2007-09-28 | 2021-02-08 | Alexion Pharma Inc | Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf |
| AU2009264282B2 (en) | 2008-06-24 | 2013-04-18 | Octapharma Ag | A process of purifying coagulation factor VIII |
| JP5709316B2 (ja) | 2008-11-14 | 2015-04-30 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法 |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| EP2453910B1 (en) * | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| EA201291482A1 (ru) * | 2010-07-09 | 2013-10-30 | Байоджен Айдек Хемофилия Инк. | Химерные факторы коагуляции |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| AU2012315516B2 (en) | 2011-09-30 | 2017-05-04 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating hemostasis |
| MX365612B (es) | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
| HK1215196A1 (zh) | 2013-01-31 | 2016-08-19 | 辉瑞公司 | 用於抵消因子xa抑制的组合物和方法 |
| AU2014326257B2 (en) | 2013-09-24 | 2017-08-10 | Pfizer Inc. | Compositions comprising heterogeneous populations of recombinant human clotting factor Xa proteins |
| CA2928762A1 (en) | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
| MX375355B (es) | 2014-01-24 | 2025-03-04 | Pfizer | Una variante del factor xa para usarse en el tratamiento de la hemorragia cerebral. |
-
2014
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016005899A8 (pt) | 2018-02-06 |
| KR20160044034A (ko) | 2016-04-22 |
| CN105579468A (zh) | 2016-05-11 |
| US20150182604A1 (en) | 2015-07-02 |
| TWI631134B (zh) | 2018-08-01 |
| AU2014326257A1 (en) | 2016-03-10 |
| IL244258A0 (en) | 2016-04-21 |
| BR112016005899A2 (pt) | 2017-09-26 |
| TW201524996A (zh) | 2015-07-01 |
| JP6429885B2 (ja) | 2018-11-28 |
| AU2014326257B2 (en) | 2017-08-10 |
| KR101988705B1 (ko) | 2019-06-12 |
| EP3049434A1 (en) | 2016-08-03 |
| CA2924981A1 (en) | 2015-04-02 |
| WO2015044836A1 (en) | 2015-04-02 |
| US20170333535A1 (en) | 2017-11-23 |
| MX2016003871A (es) | 2016-08-04 |
| RU2648144C2 (ru) | 2018-03-22 |
| IL279396A (en) | 2021-01-31 |
| PE20160877A1 (es) | 2016-09-11 |
| MX373466B (es) | 2020-05-25 |
| CA2924981C (en) | 2020-03-31 |
| RU2016108608A (ru) | 2017-10-26 |
| CN112195169A (zh) | 2021-01-08 |
| SG11201601221XA (en) | 2016-04-28 |
| US20210106658A1 (en) | 2021-04-15 |
| AR097732A1 (es) | 2016-04-13 |
| HK1218760A1 (zh) | 2017-03-10 |
| JP2016535071A (ja) | 2016-11-10 |
| US9757434B2 (en) | 2017-09-12 |
| US10660946B2 (en) | 2020-05-26 |
| SA516370751B1 (ar) | 2018-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240902A0 (en) | Powdered formulation containing thrombin and fibrinogen | |
| EP3043824A4 (en) | Modified therapeutic agents and compositions thereof | |
| DK2994173T3 (en) | Wound healing and tissue engineering | |
| SG10201802525QA (en) | Methods and compositions comprising purified recombinant polypeptides | |
| MX362155B (es) | Combinaciones de alquilamidotiazoles y sustancias aromaticas. | |
| SG11201508167PA (en) | Therapeutic compositions and uses thereof | |
| AU343215S (en) | Merchandiser | |
| IL245647A0 (en) | surgical gauze | |
| ZA201803551B (en) | Personal care composition comprising taurine, arginine, glycine | |
| IL240924B (en) | Antagonistic peptide to cxcr4 and cytarabine for the treatment of myeloid leukemia | |
| DK3007717T3 (da) | Peptider med antagonistiske aktiviteter mod naturlig cxcr4 | |
| PH12015501302A1 (en) | Compositions comprising vortioxetine and donepezil | |
| UA117933C2 (uk) | Поліпептид, здатний зв'язувати с5-компонент комплементу людини | |
| LT2948160T (lt) | Kompozicija, kurios sudėtyje yra chondroitino sulfato, natokinazės ir sulfhidrilinių junginių, skirta naudoti uždegimo gydymui | |
| IL279396A (en) | Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins | |
| GB2515113B (en) | Surgical table and method of operating the same | |
| SI2854841T1 (sl) | Glikozilacijske izooblike humanega tkivnega kalikreina-1 | |
| IL235035A0 (en) | A preparation to prevent an effect on blood vessels in the treatment of blood loss and anemia | |
| PL405129A1 (pl) | Nowe peptydomimetyki o aktywności antyangiogennej | |
| MX361222B (es) | Composiciones sellantes. | |
| PH12016500509A1 (en) | Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins | |
| BR112015008704A2 (pt) | composição fungicida compreendendo mancozeb e clorotalonil | |
| GB201310678D0 (en) | Surgical tables and methods of operating the same | |
| FR3049867B1 (fr) | Composition hemostatique et cicatrisante | |
| GB201319459D0 (en) | Karaoke collaboration for those in care and their families and trusted others |